Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive data from Afinitor trial

Novartis reports positive data from Afinitor trial

3rd June 2010

Novartis has presented data from a new clinical trial of its cancer treatment Afinitor, which demonstrates the treatment’s efficacy.

During the phase III study, it was shown that advanced pancreatic neuroendocrine tumour (NET) patients trialled using the everolimus tablet-based treatment experienced extended progression free survival, when compared to a placebo control group.

This means that the trial was able to meet its primary endpoint, with Novartis hoping to use the data to support worldwide regulatory filings later this year.

Herve Hoppenot, president of Novartis Oncology, expressed hope that the results of the trial will “bring us one step closer to our goal of offering these patients a new therapy”.

He added that the drug can potentially be “an important treatment option for patients with advanced pancreatic NET, where there is a major unmet need”.

Last week, Novartis presented new clinical data on its diabetic macular edema drug ranibizumab, demonstrating its efficacy compared to the current standard of care.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.